Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G/A for Cyclacel Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (CYCC).
- Disclosed ownership: 9.2%.
- Date of event: 31 Mar 2025.
ARMISTICE CAPITAL, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for Cyclacel Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (CYCC)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- CYCC
- Shares outstanding
- 270,051,359 shares
- Disclosed Ownership
- 24,844,725 shares
- Ownership
- 9.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 15:24:28 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 9.2% ownership in Cyclacel Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (CYCC) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 15 May 2025, 15:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 9.2% | 24,844,725 | 0 | 24,844,725 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 9.2% | 24,844,725 | 0 | 24,844,725 | /s/ Steven Boyd | Steven Boyd |